Nezve Chiremba
Dr. Ahn Jin-hee ari mumwe weakanakisa oncologist muSeoul, South Korea.
- Dr. Ahn Jin-hee dzidzo
-
- Chiremba weMishonga: Yunivhesiti yeUlsan
- Master of Medicine: Yunivhesiti yeUlsan
- Bachelor yeMishonga: Hanyang University
- Dr. Ahn Jin-hee zviitiko zvehunyanzvi
-
- Anoshanyira Muongorori paDanafaber Cancer Institute, Harvard Medical School, USA
- Sangana naPurofesa muOncology, UUCM AMC
- Mubatsiri Purofesa muOncology, UUCM AMC
- Clinical Mudzidzisi muUUCM AMC
- Kushamwaridzana muUUCM AMC
- Kugara muUUCM AMC
- Mukati meUUCM AMC
chipatara
Asan Medical Center, Seoul, South Korea
Nyanzvi
- Kansa yepabonde
- Bone & yakapfava tishu sarcoma
- Chirwere chemhondi
- Kenza yemukadzi
- Ovarian cancer
Maitiro Akaitwa
- Kurapa kenza yemazamu
- Bone & nyoro tishu sarcoma kurapwa
- Mushonga wechibereko kurapwa
- Kenza yemukenza kurapwa
- Ovarian kenza kurapwa
Tsvagiridzo & Mabhuku
| Gemcitabine uye Docetaxel Mubatanidzwa weAdvanced Soft Tissue Sarcoma: Yenyika Yese Kudzokorora Kudzidza. |
| Phase III, Randomized, Double-Blind Study Kuenzanisa Efficacy, Kudzivirirwa, uye Immunogenicity yeSB3 (Trastuzumab Biosimilar) uye Reference Trastuzumab muvarwere Vanobatwa Neoadjuvant Therapy yeHuman Epidermal Growth Factor Receptor 2-Yakanaka |
| Iyo Randomized Feasibility Kudzidza kwe (18) F-Fluoroestradiol PET Kufanotaura Pathologic Mhinduro kuNeoadjuvant Therapy muEstrogen Receptor-Rich Postmenopausal Breast Cancer. |
| Chikamu I dosi-kukwira kudzidza kweiyo c-Met tyrosine kinase inhibitor SAR125844 muAsia varwere vane advanced solid tumors, kusanganisira varwere vane MET-yakawedzera gastric cancer. |
| Phase II, multicentre, kuyedzwa kusarongeka kweeribulin pamwe gemcitabine maringe paclitaxel pamwe gemcitabine seyekutanga-chemotherapy chemakemikari mune varwere vane HER2-isina metastatic kenza yemazamu. |
| Hupenyu hwehupenyu paTSU-68: Musanganiswa weiyo docetaxel uye TSU-68, yemuromo antiangiogenic mumiririri, mune varwere vane metastatic kenza yemazamu yakamborapwa neantracycline. |
| Ongororo yakasarudzika yekugona kwe18F-fluoroestradiol positron emission tomography kufanotaura maitiro ekurwara neoadjuvant systemic kurapa muestrogen receptor-rich postmenopausal kenza yemazamu. |
| Cytoplasmic expression yekukwira inofamba boka B1 (HMGB1) inosanganisirwa nethumba-inopinda ma lymphocyte (TILs) mukenza yemazamu. |
| Yakareba-mhedzisiro mhedzisiro ye tyrosine kinase inhibitor discontinuation mune varwere vane metastatic renal cell carcinoma. |
| Monogenic uye polygenic zvinogadzirisa sarcoma njodzi: yepasi rose genetic kudzidza. |
| Inotevera-chizvarwa kuteedzana kunozivisa somatic shanduko dzinopa yakasarudzika mhinduro kune everolimus. |
| Chikamu chechipiri II kutongwa kweeoadjuvant letrozole uye lapatinib muAsia postmenopausal vakadzi vane estrogen receptor (ER) uye munhu epidermal kukura factor receptor 2 (HER2) -positive kenza yemazamu [Neo-ALL-IN]: Kusimbisa TILs, ER inoshandura shanduko aft |
| Postoperative Radiotherapy Mushure meLimb-inoregedza Kuvhiya kweSoft-tishu Sarcomas yeDistal Extremities. |
| Chikamu chekutanga chekudzidza nezve heterologous prime-boost vaccination inosanganisira truncated HER1 kuteedzana mune varwere vane HER2-inoratidza kenza yemazamu. |
| Kutenderera Plasma Biomarkers yeTSU-68, iyo Oral Antiangiogenic Agent, mune Varwere vane Metastatic Breast Cancer. |
| Clinicopathologic Kukosha kweiyo Intratumoral Heterogeneity yeHER2 Gene Kuwedzeredzwa muHER2-Positive Breast Cancer Varwere Vanobatwa NaAdjuvant Trastuzumab |
| Kufananidza kwePatologic Mhinduro Yekuongorora Masystem mushure meAnthracycline pamwe / pasina Mutero-Yakavakirwa Neoadjuvant Chemotherapy pakati peMhando dzakasiyana dzeCancer yeCancer. |
| Yakakwira yekufamba boka B1 uye N1 (HMGB1 uye HMGN1) inosanganiswa neyemota-inopinda ma lymphocyte muHER2-yakanaka kenza yemazamu |
| Kufungidzira Kukosha kweTumor-Inopindirana maLymphocyte uye iyo Tertiary Lymphoid Maumbirwo muHER2-Yakanaka Breast Cancer Inobatwa NaAdjuvant Trastuzumab. |
| Prognostic tishu biomarker kutsvaga kwevarwere vane metastatic renal cell carcinoma inogamuchira vascular endothelial kukura factor receptor tyrosine kinase inhibitors. |
